Roskilde University
Responsive
Roskilde, Denmark
Rare diseases
Investigational molecules
Locations
A plain-language summary of the goals, design and what participants do
The study examines how several commonly prescribed medicines affect a person's ability to drive safely. The medicines being tested are clonazepam, tramadol, pregabalin, gabapentin, dexamfetamine, and sodium oxybate. The condition of interest is Driving under the influence, which means impaired driving after taking a drug.
The main purpose is to determine how these drugs change driving performance. Participants will receive one of the study medicines or a placebo capsule and then, after a short waiting period, will complete a computer‑based driving simulation and a series of simple memory and reaction tests at specific times. Blood, saliva and other samples will be taken, and heart activity will be recorded with a ECG.
The driving simulation measures how well a person stays within the lane and how fast they travel. Cognitive tests include a digit span test (remembering numbers) and a reaction test (pressing a button quickly when a signal appears). Heart rhythm is monitored, and a mobile tool called the DRUID app records any feelings of impairment. Participants also answer short questionnaires about sleepiness and how they feel while driving.
The trial runs in 10 steps – from screening to follow-up. Each step says what happens and what the team monitors.
7 criteria
11 criteria
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
All sites with verified contact details – recruitment status may not be available; ask directly
Roskilde, Denmark
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
Not yet recruitingJoining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
is a medication that belongs to a group of drugs called benzodiazepines. In this study it is given by mouth to see how it might affect a person’s thinking, reaction time, and ability to drive safely. Researchers are watching for any changes in alertness, coordination, or judgment while participants take this drug.
(often known as GHB) is a central nervous system depressant that is also taken orally. The trial uses it to understand whether it can cause drowsiness, memory problems, or slower decision‑making that could make driving more difficult. Participants are monitored for any signs of reduced alertness or impaired motor skills.
is a stimulant medication that is taken by mouth. In the trial it is used to see if it can improve focus, speed of thinking, or reaction time, and whether any of these effects might make driving performance better or worse. Researchers watch for increased energy, restlessness, or changes in concentration.
is a drug taken orally that is often used for nerve pain and anxiety. The study looks at how it might affect attention, coordination, and the ability to respond quickly while driving. Participants are observed for any feelings of dizziness, drowsiness, or reduced mental sharpness.
is an oral medication commonly used for nerve pain and seizures. In this trial it is examined for its possible impact on thinking skills, reaction speed, and overall driving safety. Researchers check for side effects such as sleepiness, blurred vision, or slowed thinking.
(combined with paracetamol) is an oral pain‑relieving medication. The study evaluates whether it can cause drowsiness, affect coordination, or change a person’s ability to stay focused while driving. Participants are monitored for any signs of sedation, dizziness, or slower reaction times.
This medication is taken by mouth as a tablet. It is an approved drug used for seizure control and anxiety relief and is listed in medical references as a benzodiazepine. It works by helping the brain chemical GABA calm down nerve activity. Pharmacologically it is classed as an anticonvulsant and anxiolytic.
This drug is taken orally, usually as a liquid solution. It is a legally approved treatment for cataplexy and excessive daytime sleepiness in narcolepsy and appears in medical literature as GHB. It acts by binding to specific brain receptors that increase the calming effects of GABA. It is classified as a central nervous system depressant.
Dexamfetamine is swallowed as an oral capsule. It is an approved medication for attention‑deficit hyperactivity disorder (ADHD) and is recognized in the literature as a stimulant. It raises the levels of dopamine and norepinephrine, chemicals that help improve focus and activity. Its pharmacological class is a psychostimulant.
Pregabalin is taken by mouth in capsule form. It is a licensed drug for nerve‑pain, fibromyalgia, and certain seizure types and is listed in medical references as an anticonvulsant. It binds to a part of calcium channels in nerve cells, which reduces the release of pain‑related chemicals. It belongs to the class of anticonvulsant/analgesic agents.
Gabapentin is an oral capsule. It is approved for treating nerve pain and as an add‑on therapy for seizures, and is widely described in medical texts. It works by attaching to calcium channels on nerves, lowering the release of excitatory signals. It is classified as an anticonvulsant and analgesic.
Tramadol, combined with paracetamol, is taken as an oral tablet. It is an approved pain‑relief medicine used for moderate to severe pain and appears in medical literature as a weak opioid. It relieves pain by modestly activating opioid receptors and by increasing serotonin and norepinephrine levels. It is classified as an opioid analgesic combined with a non‑opioid analgesic.
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?
Tell us about your condition – we search every trial in Europe and connect you with the right site.